Exposure to cocaine induces selective behavioral and molecular adaptations. In rodents, acute cocaine induces increased locomotor activity, whereas prolonged drug exposure results in behavioral locomotor sensitization, which is thought to be a consequence of druginduced neuroadaptive changes. Recent attention has been given to compounds activating GABA B receptors as potential antiaddictive therapies. In particular, the principle of allosteric positive GABA B receptor modulators is very promising in this respect, as positive modulators lack the sedative and muscle relaxant properties of full GABA B receptor agonists such as baclofen. Here, we investigated the effects of systemic application of the GABA B receptor-positive modulator GS39783 (N,N 0 -dicyclopentyl-2-methylsulfanyl-5-nitropyrimidine-4, 6-diamine) in animals treated with acute and chronic cocaine administration. Both GS39783 and baclofen dose dependently attenuated acute cocaine-induced hyperlocomotion. Furthermore, both compounds also efficiently blocked cocaine-induced Fos induction in the striatal complex. In chronic studies, GS39783 induced a modest attenuation of cocaine-induced locomotor sensitization. Chronic cocaine induces the accumulation of the transcription factor DFosB and upregulates cAMP-response-element-binding protein (CREB) and dopamine-and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32). GS39783 blocked the induction/activation of DARPP-32 and CREB in the nucleus accumbens and dorsal striatum and partially inhibited DFosB accumulation in the dorsal striatum. In summary, our data provide evidence that GS39783 attenuates the acute behavioral effects of cocaine exposure in rodents and in addition prevents the induction of selective long-term adaptive changes in dopaminergic signaling pathways. Further investigation of GABA B receptor-positive modulation as a novel therapeutic strategy for the treatment of cocaine dependence and possibly other drugs of abuse is therefore warranted.
INTRODUCTION
In rodents, a behavioral consequence of acute cocaine administration is increased locomotor activity, whereas chronic cocaine induces locomotor sensitization, which results in an enduring enhancement of behavioral responses during repeated drug administration (Kalivas and Stewart, 1991) . The motor stimulant effects of cocaine are thought to be mediated via an increase in dopaminergic transmission in the mesocorticolimbic system. Cocaine inhibits dopamine (DA), norepinephrine, and serotonin reuptake and thereby causes an increase in synaptic concentrations of these neurotransmitters. In the nucleus accumbens (NAc), elevated DA levels cause a dysregulation of D1/D2-like DA receptor signaling, which in turn leads to the upregulation of several molecular markers (Anderson and Pierce, 2005) . Fos is a marker of cell activation and is upregulated in the striatum by acute cocaine (Graybiel et al, 1990) . DFosB, a truncated form of FosB, slowly accumulates in NAc and dorsal striatum during chronic drug exposure (Hope et al, 1994) . Acute and chronic cocaine administration increases the expression of cAMP-response-element-binding protein (CREB) and dopamine-and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) in the NAc (Terwilliger et al, 1991; Kano et al, 1995; Nishi et al, 2000 , Bibb et al, 2001 .
There is accumulating evidence indicating that GABA B receptor activation could be beneficial in the treatment of cocaine dependence. In rodents, the GABA B receptor agonist baclofen blocks cocaine-induced hyperlocomotion (Kalivas and Stewart, 1991) and cocaine-conditioned hyperlocomotion (Hotsenpiller and Wolf, 2003) . Furthermore, baclofen has shown efficacy in human clinical trials in reducing cocaine, opiate, and alcohol craving (Addolorato et al, 2002; Brebner et al, 2002; Shoptaw et al, 2003; Cousins et al, 2002 ). Baclofen's mechanism of action likely involves modulation of dopaminergic neuronal activity in the ventral tegmental area (VTA). Intra-VTA application of baclofen attenuates cocaine self-administration (Brebner et al, 2000) . Furthermore, VTA neurons release DA in the NAc and prefrontal cortex (Kalivas, 1993) and baclofen antagonizes nicotine-, cocaine-, and morphine-induced DA release in the NAc (Fadda et al, 2003) . Postsynaptic GABA B receptors reduce cell excitability through the activation of potassium channels, whereas activation of presynaptic receptors, via Ca 2 + channel inhibition, reduces the release of various neurotransmitters (Bettler et al, 2004) . In the VTA, GABA B receptors are expressed on dopaminergic cell bodies . Activation of these receptors would be expected to hyperpolarize DA neurons, thereby functionally counteracting the effects of cocaine.
Baclofen, however, induces unwanted side effects such as muscle relaxation and sedation. Positive GABA B receptor modulators such as GS39783 (N,N 0 -dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4, 6-diamine) are active only in the presence of GABA and are devoid of the sedative and muscle relaxant effects of full agonists (Urwyler et al, 2003; Cryan et al, 2004) . GS39783 reduces the acute rewarding effects of cocaine self-administration in rodent models (Smith et al, 2004; Slattery et al, 2005) . However, the effects of GS39783 on the long-term behavioral and molecular consequences of cocaine exposure are unknown.
The goals of the present study were two-fold. The first objective was to assess the efficacy of GS39783 in modulating the locomotor effects of acute and chronic cocaine exposure. Our second objective was to investigate the effects of GS39783 on specific molecular markers of DA signaling affected by cocaine exposure, in order to elucidate molecular pathways underlying the antiaddictive properties of GABA B receptor-positive modulation.
MATERIALS AND METHODS

Animals
Male C57BL/6J mice (18-20 g) were obtained from Charles River, France. Housing was at room temperature, in a 12 h light/dark cycle with lights on at 06:00. Food pellets and tap water were available ad libitum. All behavioral experiments were conducted during the light cycle. All animals were experimentally naïve, unless otherwise noted. Experiments were subject to institutional review and conducted in accordance with the Veterinary Authority of Basel-Stadt, Switzerland.
Acute Cocaine-Induced Hyperactivity
The effects of cocaine, baclofen, and GS39783 on locomotor activity were assessed in commercially available test chambers (19 Â 31 Â 16 cm) (TSE, Bad Homburg, Germany). Activity was recorded using the TSE Moti system, which is based on the registration of infrared light beam interruptions along the x-, y-, and z-axis, as caused by an animal's movements . Mice were individually placed in test chambers. After 30 min of habituation, GS39783 (10, 30, and 100 mg/kg per os (p.o.)), baclofen (3 and 6 mg/kg p.o.), or methylcellulose was applied and the locomotor activity was recorded. After 30 min, mice were injected with cocaine (10 mg/kg intraperitoneal (i.p.)) or saline and locomotor activity was recorded for additional 60 min. Doses of GS39783 were selected based on previous studies showing activity in anxiety models at this dose range . The doses of baclofen were selected based on them being maximal doses before behavioral inhibition occurs Jacobson and Cryan, 2005) . The dose of cocaine was selected as it produced a robust hyperactivity in previous studies (Cryan et al, unpublished) .
Chronic Cocaine-Induced Locomotor Sensitization
The mice were habituated to the test environment for 3 days and basal locomotor activity was measured. After an i.p. injection of saline, the mice were placed in the test cages (as above) for 30 min and locomotor activity was recorded. From days 4 to 10, mice were injected with cocaine (20 mg/ kg i.p.) or saline and locomotor activity was recorded. To assess the effects of GABA B receptor-positive modulation on the acquisition of behavioral sensitization to cocaine, GS39783 (30 mg/kg p.o.) or vehicle (0.5% methylcellulose) was applied 30 min before each cocaine injection. This period of acquisition of sensitization was followed by 14 days without drug treatment. In order to investigate the effect of GS39783 on the expression of cocaine sensitization, we designed a challenge trial (see, eg Kalivas and Stewart, 1991) . On day 26 (challenge day), mice were administrated a dose of 10 mg/kg i.p. cocaine. To assess the effect of GABA B receptor-positive modulator on the expression of sensitization, GS39783 (30 mg/kg p.o.) or methylcellulose was applied 30 min before the cocaine injection.
Tissue Preparation
In studies addressing the effects of acute cocaine administration, mice were killed 2 h after drug application. Chronically treated animals were killed 24 h after the last cocaine administration. Brains were quickly removed, chilled in ice-cold phosphate-buffered saline (PBS), and cut in 1-mm-thick slices using a mouse brain matrix (RBM 2000C, Asi Instruments). NAc and dorsal striatum were dissected on an ice-chilled glass plate and flash-frozen in dry ice.
Immunoblotting
Individual tissue samples for Western blot analysis were homogenized with a glass-glass homogenizer in ice-cold buffer containing (in mM) Hepes (pH 7.9) 20, NaCl 400, MgCl 2 5, EDTA 0.5, EGTA 0.1, including complete protease (Roche) and phosphatase inhibitors (Sigma). Homogenates were kept 20 min on ice and centrifuged 15 min at 20 000 g, 41C. Pellets containing particulate fractions enriched in organelles and nuclei were mixed with 2 Â Laemmli sample buffer (125 mM Tris (pH 6.8), 4% (w/v) sodium dodecyl sulfate (SDS), 0.005% (w/v) bromophenol blue, 200 mM dithiothreitol, 20% glycerol), heated to 901C for 5 min, and loaded on 10% SDS acrylamide gels (Bio-Rad). After electrophoretic transfer (Bio-Rad blotting device), nitrocellulose membranes were incubated 1 h at room temperature in PBS containing 0.1% Tween 20 and 5% fat-free powdered milk (PBST/milk). After three washes in PBST, the membranes were incubated overnight at 41C with primary antibodies in PBST/milk, and washed again three times in PBST. Incubation with horseradish-peroxidase (HRP)-conjugated secondary antibody was for 1-2 h at room temperature. Peroxidase activity was detected using Supersignal West Pico substrate (Pierce) and Kodak MR-1 X-ray films (Amersham Biosciences). Afterwards, bound antibodies were removed (restore buffer, Pierce) and the membranes were incubated with an anti-actin antibody to check for loading. X-ray films were scanned and analyzed with NIH ImageJ software (http://rsb.info.nih.gov/ij/, v1.31) according to the manufacturer's indications. Intensity values are presented as the ratio of the optical density of the band of interest and of its actin control. Individual samples were not pooled and care was taken not to overexpose X-ray films in order to ensure linearity of signals. All experiments were performed in duplicate or triplicate.
Statistical Analysis
In behavioral experiments, time courses of motor activity were analyzed using an appropriate two-way or three-way ANOVA with one repeated measure (time) followed by, where appropriate, Fisher's post hoc tests. In molecular studies, significance was assessed by a one-way ANOVA, followed by post hoc Newmann-Keuls test.
Reagents
Cocaine was obtained from Sigma (St Louis, MO). Lbaclofen and GS39783 were synthesized in-house. All drug solutions were made up fresh before use. Primary antibodies used were rabbit anti-Fos (sc-253, Santa Cruz Biotechnology, 1:1000), rabbit anti-FosB (sc-48, Santa Cruz Biotechnologies, 1:500), mouse anti-phosphorylated CREB (pCREB) (clone 1B6, Cell Signaling, 1:1000), rabbit anti- DARPP-32 (2302 , Cell Signaling, 1:2000 , rabbit anti-CREB (sc-58, Santa Cruz Biotechnology, 1:1000), and rabbit antiactin (A2066, Sigma, 1:5000). Secondary antibodies were HRP-linked goat anti-mouse IgG (1:2000, Bio-Rad) or goat anti-rabbit IgG (7074, Cell Signaling, 1:1000-1:5000). All other reagents were from Sigma.
RESULTS
GABA B Receptor Activation Attenuates CocaineInduced Hyperlocomotion
In rodents, a behavioral consequence of acute cocaine administration is increased locomotor activity. We used locomotor activity as readout to assess the behavioral effects of baclofen and GS39783 on cocaine exposure. A single injection of cocaine (10 mg/kg i.p.) resulted in a marked increase in ambulatory activity, compared with administration of saline (Figure 1 Groups that differed significantly from vehicle-treated animals (po0.05, po0.01, po0.001, respectively). The arrows indicate the time point of saline or cocaine injection; baclofen or GS39783 were applied 30 min before saline/cocaine.
with the GABA B receptor agonist baclofen or with the positive modulator GS39783 (F 5,131 ¼ 8.807; po0.001), and a cocaine Â treatment interaction (F 5,131 ¼ 6.009; po0.001). Post hoc analysis revealed that baclofen at 6 mg/kg lowered spontaneous locomotor activity at 0-10 min time point in animals injected with saline (po0.05; Figure 1a ). Unexpectedly, animals that had been administered baclofen (3 mg/ kg) 30 min before saline injection had a brief, exaggerated increase in locomotor activity immediately after saline injection which normalized 10 min later ( Figure 1a ). Inspection of the locomotor response in individual animals revealed that only three out of 12 animals showed this increased locomotor activity after application of 3 mg/kg baclofen. We did not observe this phenomenon after treatment with higher doses of baclofen and thus the physiological relevance of this observation remains unclear. In contrast to baclofen, GS39783 (at 10, 30, and 100 mg/kg) did not affect spontaneous locomotor activity ( Figure 1c ).
The effects of baclofen and GS39783 on cocaine-induced locomotor activity are shown in Figure 1b and d. Post hoc analysis revealed that both GS39783 and baclofen blunted the stimulatory effect of cocaine. Although baclofen significantly attenuated cocaine-induced hyperactivity at all doses investigated (Figure 1b) , interpretation of the effect obtained with the higher dose (6 mg/kg) is confounded by baclofen's sedative properties as evidenced by reduced basal activity at this dose ( Figure 1a and b). The GABA B receptorpositive modulator GS39783 significantly attenuated hyperlocomotion between 10 and 60 min after cocaine administration ( Figure 1d ). However, in contrast to baclofen, GS39783 did not affect basal locomotor activity. No signs of stereotypic behavior after baclofen or GS39783 application were observed. Taken together, these data suggested that activation of GABA B receptors with the agonist baclofen or with the positive modulator GS39783 can attenuate the locomotor stimulation induced by a single administration of cocaine. Further, we confirmed previous observations showing that GS39783 is devoid of sedative properties of the GABA B receptor agonist baclofen .
Striatal Fos Upregulation by Acute Cocaine is Inhibited by GABA B Receptor Activation
To date, in the context of drug addiction only few studies have focused on the investigation of the molecular mechanisms affected by potential therapeutic strategies, including those focused on GABA B receptors. One of the most robust responses to acute cocaine is the activation of immediate-early gene expression, most notably Fos (Curran et al, 1996; Graybiel et al, 1990) . To investigate a possible effect of GABA B receptor activation on cocaine-induced Fos upregulation, we conducted an experiment with a separate group of animals. The mice were treated with baclofen, GS39783, or saline 30 min before cocaine or saline injection. Effects of the GABA B Receptor-Positive Modulator GS39783 on the Acquisition of Cocaine Sensitization
Chronic cocaine induces locomotor sensitization, which results in an enduring enhancement of behavioral responses during repeated drug administration (Kalivas, 1993) . In behavioral sensitization studies, at least two different phases are recognized, acquisition and expression (Pierce and Kalivas, 1997) . Briefly, acquisition is the phase in which behavioral and physiological changes develop owing to repeated, intermittent exposure to psychostimulants. The expression phase defines the long-term behavioral changes that are the result of drug-induced neuroadaptations.
We measured locomotor activity of mice immediately after daily cocaine injection for 30 min during the 7 days of acquisition phase (Figure 3) Figure 1d , GS39783 attenuated the hyperlocomotion induced by a single administration of cocaine ( Figure 3 , day 4; po0.01). In addition, post hoc analysis revealed that mice treated daily with cocaine and GS39783 exhibited less hyperactivity than mice treated with cocaine alone (days 7-10; Figure 3 ). We observed persistent significant effects only after 3 days of GS39783 treatment; thus, these data may be interpreted as a delayed response after drug application. However, cocaine-induced sensitization increases with time and the marked increase in locomotor activity between treatment days 6 and 7 could be the reason why the effects of GS39783 are more pronounced and significant only at this protracted stage. Repeated treatments of GS39783 did not affect locomotor activity compared with the vehicle-treated group, confirming the absence of sedative properties of GS39783. It is noteworthy that GS39783 only modestly attenuated sensitization, as mice treated with chronic cocaine in combination with GS39783 still appeared sensitized compared to salinetreated controls. Further, it is difficult to disentangle GS39783 effects on sensitization from its ability to suppress cocaine-induced hyperactivity acutely.
In order to further examine the effect of GS39783 on locomotor sensitization, we designed a cocaine challenge trial, 14 days after the last cocaine injection (Kalivas and Stewart, 1991) . During this challenge, all mice received 10 mg/kg of cocaine (Figure 4) . Three-way ANOVA revealed significant effects of repeated cocaine treatment between days 4 and 10 (F 1,63 ¼ 113.408; po0.001). These data confirmed the presence of behavioral cocaine sensitization. There was an effect of GS39783 when administered during the acquisition period (F 1,63 ¼ 4.708; p ¼ 0.034) and before the challenge (F 1,63 ¼ 6.795; p ¼ 0.005), and an interaction between repeated cocaine treatment and GS39783 administrated during the acquisition phase (F 1,63 ¼ 4.022; p ¼ 0.049). As expected, mice treated repeatedly with cocaine exhibited an enhancement of total distance traveled compared to mice treated only with the challenging dose of cocaine (Figure 4 , groups 3 vs 1; po0.001). Mice treated concomitantly with GS39783 and cocaine during the acquisition phase exhibited significantly less locomotor activity compared to mice treated only with cocaine ( Figure 4 , groups 7 vs 3; po0.05), suggesting once again that GS39783 moderately attenuates the acquisition of behavioral sensitization to cocaine. Cocaine-sensitized mice pretreated with GS39783 before the cocaine challenge did not differ significantly in their locomotor response compared with mice receiving only the challenging dose of cocaine (Figure 4 , groups 4 vs 3), suggesting that GS39783 does not affect the expression of sensitization. However, we note that in this experiment a single application of GS39783 failed to significantly reduce hyperlocomotion in control group 2 (vs group 1). Therefore, our data do not allow for definite conclusions on the potential effects of GS39783 on the expression of cocaine sensitization. Dual administration of GS39783 during the acquisition and before the challenge reduced cocaine-induced increases in locomotor activity (Figure 4 , groups 8 vs 3; po0.01). Again, it is important to reinforce that it is difficult to discriminate acute effects of GS39783 on cocaine-induced hyperactivity from that on the acquisition of sensitization. Further, as in the experiments described under Figure 3 , we observed that animals treated with chronic cocaine in combination with GS39783 were still sensitized at the cocaine challenge as shown by increased locomotor activity compared to saline controls. In summary, GS39783 application had only a modest effect on the acquisition of sensitization. (10, 30, and 100 mg/kg p.o.) attenuates cocaine-induced Fos upregulation in dorsal striatum (e) and NAc (f) samples. *, + indicate differences to saline controls or cocaine groups, respectively; o indicates differences within treatment groups. *, + , o, po0.05; **, + + , po0.01; ***, + + + , po0.001; a.u., arbitrary units.
GS39783 Blunts Chronic Cocaine-Associated DFosB Upregulation in Dorsal Striatum
In the mesolimbic circuit, chronic cocaine administration triggers the accumulation of DFosB, which is thought to play a pivotal role in long-lasting effects of a variety of drugs of abuse including cocaine. Overexpression of DFosB increases the sensitivity to cocaine and the motivational aspects of reward (Kelz et al, 1999; Colby et al, 2003) . We studied DFosB expression after 7 days of daily treatment with saline/cocaine or GS39783/cocaine ( Figure 5 ). The animals were killed 24 h after the last administration. A separate group of animals from those used in behavioral studies were used. DFosB expression was measured using semiquantitative Western blot analysis employing selective antibodies (Zhang et al, 2002; Muller and Unterwald, 2005) . Cocaine stimulated a robust increase in DFosB expression in dorsal striatum (Figure 5a ; po0.001 vs saline) that was partially blocked by GS39783 (po0.05). In NAc, DFosB levels were also upregulated by chronic cocaine (Figure 5b ; po0.001); however, in this brain region, GS39783 failed to modulate DFosB induction by cocaine (p ¼ 0.92). Basal levels of DFosB expression were not affected in either structure (p40.1). During protracted withdrawal, DFosB levels decrease to basal levels, that is, 10-12 days after cessation of chronic cocaine treatment (Hope et al, 1994; Perrotti et al, 2005) . In line with these observations, we did not detect DFosB 14 days after cessation of cocaine-repeated administration (Figure 5c ). Chronic treatment with GS39783 before withdrawal had no effect on DFosB levels. In summary, our data therefore suggest that the mode of action of GS39783 has a modest impact on cocainemodulated DFosB expression in the dorsal striatum but not in NAc.
GS39783 Blocks Chronic Cocaine-Induced Upregulation and Activation of DARPP-32 and CREB
Previous studies have shown that chronic cocaine induces a strong activation of DARPP-32 and CREB through increased DA signaling (Kano et al, 1995; Bibb et al, 2001) . We therefore examined whether such changes in DARPP-32 and CREB are modulated by GS39783 (Figures 6 and 7 ). An experimental setup identical to the DFosB studies as described above was used. In the dorsal striatum, a small, nonsignificant reduction of DARPP-32 expression was observed after treatment with cocaine or GS39783 (F 3,50 ¼ 2.44; p ¼ 0.07; Figure 6 ). In NAc however, chronic cocaine stimulated DARPP-32 expression. In agreement with previous studies (Lin et al, 2002; Hu et al, 2005) , chronic cocaine administration increased DARPP-32 expression in NAc (po0.001), but not in the dorsal striatum. DARPP-32 upregulation was not observed when GS39783 was applied 30 min before each daily cocaine administration (po0.001). GS39783 did not affect basal DARPP-32 levels (p40.1; Figure 6b ). CREB is activated by phosphorylation and this active form is shuttled to the nucleus where it drives expression of its target genes (Shaywitz and Greenberg, 1999) . In addition to total CREB, we investigated the levels of pCREB, and determined the pCREB/CREB ratios. In the dorsal striatum, cocaine and GS39783 had a minor effect and the ratio of pCREB/CREB remained unmodified (Figure 7a ; F 3,81 ¼ 1.75; p ¼ 0.16). In the NAc, chronic cocaine increased CREB activation as evidenced from the pCREB/CREB ratio, Figure 3 Effects of GS39783 application during the acquisition phase of cocaine sensitization. Mice (n ¼ 18) were habituated to the locomotor activity chambers during three daily sessions (days 1-3) of 30 min after receiving i.p. saline injection. GS39783 (30 mg/kg p.o.) or vehicle was administrated 30 min before cocaine injection (20 mg/kg i.p.) on 7 consecutive days (days 4-10). Locomotor activity was recorded immediately after cocaine injection for 30 min. Values are means (n ¼ 18 per group)7SEM of the total distance traveled during the total 30 min of daily session. Groups that differed significantly from cocaine-treated animals are indicated (**po0.01; ***po0.001). Figure 4 Effects of GS39783 on the acquisition and expression of cocaine sensitization. The effects of different GS39783 regimen (30 mg/kg p.o.) on hyperactivity induced by a challenging dose of cocaine (10 mg/kg i.p., day 26) injected after 14 days of drug-free period are shown (n ¼ 8-9 mice per group). Treatment during the acquisition phase (days 4-10) was as described in Figure 3 . Bar graphs show means7SEM of the total distance traveled during the 30 min of challenge session. * and **Groups that differed significantly from cocaine-sensitized animals (po0.05 and po0.01, respectively).
confirming previous studies (Figure 7b ; po0.01, Terwilliger et al, 1991; Kano et al, 1995) . Calculation of the pCREB/ CREB ratios demonstrated that GS39783 effectively inhibited chronic cocaine-induced CREB stimulation (Figure 7b ; po0.01).
DISCUSSION
Although molecular adaptations to chronic cocaine have been hypothesized to play a major role in the manifestation of cocaine dependence (Nestler and Aghajanian, 1997) , very few studies to date have investigated the ability of potential therapeutic agents to modulate such responses. In the present study, we have demonstrated that systemic application of the GABA B receptor-positive allosteric modulator GS39783 attenuates cocaine-induced locomotor activity and is also effective in preventing the induction of several molecular markers of acute or chronic cocaine exposure.
Both the GABA B receptor agonist baclofen and the positive modulator GS39783 attenuated the hyperlocomotion induced by a single administration of cocaine. Further, we have shown that GS39783 attenuated, albeit modestly, the acquisition of cocaine sensitization. GS39783 induced similar effects as a nonsedative dose of baclofen (3 mg/kg) in attenuating acute cocaine-induced hyperlocomotion (Figure 1 Figure 5 GS39783 has a weak inhibitory effect on DFosB induction by chronic cocaine. Mice (n ¼ 5-10 animals/experimental group) were treated daily with cocaine (20 mg/kg i.p.), GS39783 (30 mg/kg p.o.), saline (À), and respective combinations as indicated on 7 consecutive days. Twenty-four hour after the last treatment, the mice were killed and NAc and dorsal striatum dissected and processed for immunoblot analysis. Representative immunoblots (top panels) and averaged densitometry values (bottom panels) are shown. The molecular weight of the DFosB isoform analyzed is indicated in kDa. (a, b) Cocaine induces DFosB upregulation in NAc and dorsal striatum. GS39783 partially inhibits DFosB induction in dorsal striatum (a) but not in NAc (b). (c) Mice (nine animals/group) were administered saline/cocaine for 7 days, after which cocaine exposure was stopped for 14 days. Then, the mice received a cocaine challenge (10 mg/kg i.p.) 24 h after which NAc samples were processed for immunoblotting. DFosB protein levels are high immediately after repeated cocaine treatment (24 h of withdrawal), whereas expression levels decline to basal levels after 14 days of cessation of chronic cocaine. * and + represent differences to saline or cocaine groups, respectively; *, + , po0.05; ***, + + + , po0.001. 2003). The observations that GS39783, in contrast to baclofen, does not alter baseline locomotor activity is in agreement with the lack of effects in other behavioral tests in both rats and mice, which are sensitive to baclofen administration; these include the rotarod motor coordination task, cognitive tasks, and hypothermia measurements Jacobson and Cryan, 2005) . Of note, the effects of GABA B receptor ligands on cocaine-induced hyperactivity appear not as robust as that reported with D1-selective DA receptor antagonists such as SCH23390, which almost completely block the locomotor stimulant effects of cocaine (O'Neill et al, 1999; Adams et al, 2001 ). However, a thorough evaluation of GABA B receptor-positive modulators in comparison to other drugs attenuating locomotor stimulant effects of cocaine requires sideby-side experiments and a careful investigation of their side-effect profile, which may influence locomotor-based behavioral readouts. It is evident that the locomotor effects of stimulant drugs and their reinforcing effects are not homologous. Therefore, further investigation of GABA B receptor modulators in animal models of reward and addiction are necessary.
35-37 -
Locomotor activity is critically dependent on the activation of dopaminergic neurotransmission (Kuczenski, 1983) . A pivotal role of VTA DA neurons in mediating the hyperlocomotor effects of DA has been described (Kalivas and Stewart, 1991) . VTA DA neurons project to numerous limbic loci including the NAc and the prefrontal cortex. Activation of GABA B receptors on the cell bodies of VTA DA neurons reduce their excitability, which in turn leads to a reduction in DA release in the NAc (Olpe et al, 1977; Lacey, 1993; Westerink et al, 1996; Wirtshafter and Sheppard, 2001) . In addition, the activity of VTA DA neurons is modulated by excitatory (glutamatergic) and inhibitory (GABAergic) afferents. Activation of GABA B receptors on glutamatergic afferents would reduce excitatory inputs into the VTA (Johnson and North, 1992; Wu et al, 1999; Hotsenpiller and Wolf, 2003) . In support of a key role of GABA B receptors in the VTA in blocking cocaineinduced hyperlocomotion, baclofen pretreatment dose dependently reduced nicotine-, morphine-, and cocaineevoked DA release in the NAc (Fadda et al 2003) . Furthermore, baclofen injection into the VTA blocked an increase in firing of NAc neurons induced by rewardpredictive cues (Yun et al, 2004) . GABA B receptor-positive modulators such as GS39783 are devoid of intrinsic agonistic activity (Urwyler et al, 2003; Cryan et al, 2004) . Their action therefore is dependent on the presence of GABA (ie synaptically released GABA). Several lines of evidence suggest that VTA DA neurons are under tonic inhibitory control by GABA B receptors. Intra-VTA application of the selective GABA B receptor antagonist CGP55845A increased extracellular DA levels (Giorgetti et al, 2002) . Furthermore, systemic application of the GABA B receptor antagonist CGP35348 increased firing of VTA DA neurons (Erhardt et al, 2002) , whereas the GABA B receptor-positive modulator CGP7930 decreased the firing frequency of VTA DA neurons in midbrain slice preparations (Chen et al, 2005) . Taken together with the data for baclofen as described above, these studies suggest that GABA B receptor-positive modulators such as GS39783 may attenuate effects of cocaine by decreasing VTA DA neuron excitability. However, contributions of other components of the mesocorticolimbic circuitry such as the ventral pallidum or the prefrontal cortex are also possible (Gong et al, 1998; Kalivas and Volkow, 2005) . Interestingly, Liu et al (2005) recently reported that cocaine exposure in vivo facilitates LTP formation in midbrain DA neurons and that druginduced synaptic plasticity could be prevented by enhanced GABAergic inhibition. The consequence of GABA B receptor activation on the formation of drug-associated memories, however, has not yet been investigated.
We have demonstrated that the modulation of several molecular markers by chronic cocaine exposure is attenuated by GS39783. In the NAc, GS39783 blocked the induction of both CREB (as evidenced by the ratio of pCREB/CREB) and DARPP-32, without affecting basal levels (Figures 6 and 7) . Cocaine treatment increases synaptic DA , and respective combinations as indicated. Dorsal striatum and NAc samples were dissected 24 h after the end of treatment. pCREB/CREB ratios were calculated from immunoblots (n ¼ 5-10); representative blots are shown (top panels, molecular weights in kda). GS39783 does not modify CREB expression in dorsal striatum (a) but inhibits cocaine-induced CREB activation in NAc (b). * and + mark differences to saline or cocaine groups, respectively; **, + + , po0.01.
concentrations, which in turn causes a dysregulation of DA receptor signaling. In the NAc, this leads to an upregulation of the adenylyl cyclase signaling pathway, via increased D1-like DA receptor activity (Anderson and Pierce, 2005) . Increased cAMP pathway activation in turn augments the expression and activation by phosphorylation of CREB and DARPP-32 (Terwilliger et al, 1991; Kano et al, 1995; Bibb et al, 2001) . Therefore, most likely, GS39783 attenuated CREB and DARPP-32 induction through GABA B receptormediated reduction of DA neuron excitability, thus preventing selective cocaine-induced changes in DA receptor signaling. Furthermore, GABA B receptors negatively couple to adenylyl cylase (Bettler et al, 2004) . GS39783-mediated inhibition of cAMP formation would be expected to decrease the effect of DA receptor signaling-induced upregulation of the adenylyl cyclase pathway, in addition to reducing DA neuron excitability. Fos expression can be stimulated by a variety of regulators including CREB. After acute treatment, Fos is induced in NAc and striatum by several drugs of abuse, including cocaine (Graybiel et al, 1990; Young et al, 1991; Curran et al, 1996; Zhang et al, 2002; Zhang et al, 2004; Nye et al, 1995) . Leite-Morris et al (2002) provided evidence that baclofen treatment in the VTA blocks Fos immunoreactivity in the NAc, by inhibiting the activation of dopaminergic neurons. We have shown that systemic applications of either baclofen or GS39783 effectively blocked cocaineinduced Fos induction. These data are in line with the observed attenuation of acute behavioral effects of cocaine and support the hypothesis that GABA B receptor activation inhibits the activation of dopaminergic neurons after cocaine treatment. DFosB is accumulated in different brain regions in response to various chronic stimuli including cocaine. We observed an increase of DFosB levels subsequent to a chronic cocaine treatment regimen in the NAc, and to a lesser extent in the dorsal striatum ( Figure 5 ), in agreement with previous studies (Hope et al, 1994; Nye et al, 1995; McClung et al, 2004) . Interestingly, GS39783 did not significantly affect DFosB upregulation in NAc but attenuated the induction in the dorsal striatum. DFosB induction is D1-like DA receptor dependent, but very little information is available about the downstream signaling cascades/transcription factors responsible for its induction (Nye et al, 1995; McClung and Nestler, 2003) . It is conceivable that DFosB expression is regulated via several tissue-specific signaling pathways, which could explain the differential effects of GS39783 on DFosB induction in NAc vs dorsal striatum.
We have shown that GS39783 only modestly attenuated the acquisition of behavioral sensitization to cocaine. However, several molecular adaptations after chronic cocaine exposure such as the induction of DARPP-32 and CREB in NAc were totally suppressed by GS39783 treatment. Thus, there is a significant dissociation between the molecular sequelae of chronic cocaine and cocaineinduced locomotor sensitization. Further investigation of the effects of GS39783 in addiction models sensitive to the effects of chronic cocaine are now called for. Such studies will be important to test if the dissociation between the behavioral and molecular consequences of chronic cocaine generalizes to more reward-related aspects of cocaine dependence and its potential treatment.
In summary, our data demonstrate that use-dependent activation of GABA B receptors, via positive modulation, can decrease both behavioral as well as long-term adaptive molecular changes in DA signaling pathways after cocaine exposure. Possible modes of action include a reduction of excitability of DA neurons but also negative coupling of GABA B receptors to adenylyl cyclase, which may counteract the increased cAMP pathway activation observed after cocaine exposure (Anderson and Pierce, 2005) . It seems evident that several facets to the addiction process need to be addressed in order to develop successful pharmacotherapeutic strategies. Therefore, interventions should not be limited to inhibiting the rewarding effects of a drug, but should also include strategies to enhance the saliency value of natural reinforcers, strengthen inhibitory control, decrease conditioned responses, and improve withdrawal-induced deficits in mood and anxiety (Volkow and Li, 2004) . The fact that GABA B receptor-positive modulators reduce anxiety in preclinical paradigms and attenuate selective molecular adaptations subsequent to chronic cocaine administration suggests that they may assist in the treatment of addiction beyond simply reducing the primary rewarding effects of the reinforcer.
